MX2024006799A - Metodos para el tratamiento de cáncer con prame positivo. - Google Patents

Metodos para el tratamiento de cáncer con prame positivo.

Info

Publication number
MX2024006799A
MX2024006799A MX2024006799A MX2024006799A MX2024006799A MX 2024006799 A MX2024006799 A MX 2024006799A MX 2024006799 A MX2024006799 A MX 2024006799A MX 2024006799 A MX2024006799 A MX 2024006799A MX 2024006799 A MX2024006799 A MX 2024006799A
Authority
MX
Mexico
Prior art keywords
dose
range
tcr
fusion molecule
administration
Prior art date
Application number
MX2024006799A
Other languages
English (en)
Spanish (es)
Inventor
Shannon Marshall
Mohammed Dar
Shaad Abdullah
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of MX2024006799A publication Critical patent/MX2024006799A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024006799A 2021-12-01 2022-11-30 Metodos para el tratamiento de cáncer con prame positivo. MX2024006799A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163285044P 2021-12-01 2021-12-01
US202263374222P 2022-08-31 2022-08-31
PCT/EP2022/083952 WO2023099622A1 (en) 2021-12-01 2022-11-30 Treatment

Publications (1)

Publication Number Publication Date
MX2024006799A true MX2024006799A (es) 2024-08-22

Family

ID=84688213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006799A MX2024006799A (es) 2021-12-01 2022-11-30 Metodos para el tratamiento de cáncer con prame positivo.

Country Status (9)

Country Link
US (1) US20250333504A1 (https=)
EP (1) EP4441096A1 (https=)
JP (1) JP2024542682A (https=)
KR (1) KR20240114759A (https=)
AU (1) AU2022402322A1 (https=)
IL (1) IL312981A (https=)
MX (1) MX2024006799A (https=)
TW (1) TW202330589A (https=)
WO (1) WO2023099622A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202519257A (zh) 2023-08-01 2025-05-16 英商英美偌科有限公司 治療皮膚黑色素瘤之方法
TW202544042A (zh) 2024-03-13 2025-11-16 英商英美偌科有限公司 治療prame陽性癌症之方法
WO2025224692A1 (en) 2024-04-25 2025-10-30 Immunocore Limited Method of treating cancer using a gene expression signature

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
WO2017208018A1 (en) * 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
TW202330589A (zh) 2023-08-01
EP4441096A1 (en) 2024-10-09
JP2024542682A (ja) 2024-11-15
WO2023099622A1 (en) 2023-06-08
KR20240114759A (ko) 2024-07-24
US20250333504A1 (en) 2025-10-30
AU2022402322A1 (en) 2024-06-20
IL312981A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
MX2024006799A (es) Metodos para el tratamiento de cáncer con prame positivo.
JP2025020134A5 (https=)
PE20221338A1 (es) Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
MX2021005438A (es) Metodos para reducir el tama?o de tumores hipofisarios.
JP2018526460A5 (https=)
MX2025005134A (es) Regimen de dosificacion intermitente de azenosertib en el tratamiento del cancer
ZA202303456B (en) Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen
JP2025148449A5 (https=)
JOP20230243A1 (ar) طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
CN102526024B (zh) 一种抗癌药物组合物
ZA202308034B (en) Interferon-based cancer treatment method, and pharmaceutical combination
JP2020524164A5 (https=)
CN108014337B (zh) 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物
NZ781127A (en) Mirikizumab for use in a method of treating crohn’s disease
NZ767902A (en) Methods of treating ulcerative colitis
NZ773583A (en) Methods of treating psoriasis
Morgan Adherence to ibrutinib therapy improves outcomes in patients with CLL
NZ781127B2 (en) Mirikizumab for use in a method of treating crohn's disease
RU2233664C2 (ru) Способ лечения красного плоского лишая
Roila et al. Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients
Olmi et al. 420 Conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus conventional radiotherapy and concomitant chemotherapy in advanced oropharyngeal carcinoma: A randomized clinical trial
CN108014336B (zh) 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物
Kamishov Clinical estimation of efficiency of coherent immunopharmacotherapy in complex treatment of uterine cervical cancer
Paszkiewicz-Kozik et al. Safety and Early Efficacy of Obinutuzumab in Combination with Chemotherapy in Treatment Naive Patients with Follicular Lymphoma-Report of Polish Lymphoma Research Group (PLRG)